Xentria Inc. Innovation at Its Finest

Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval. Infliximab ... Xentria, a Chicago, IL-based biotech company, raised $25M in Equity funding. Xentria will license its experimental pulmonary sarcoidosis drug to Meitheal Pharmaceuticals in a deal worth up to $680 million. Keymed Biosciences Co.Ltd · Fondazione Policlinico Universitario Agostino Gemelli... Terminado · Xentria, Inc. Terminado · Serum Institute of India ... Xentria, Inc. USA, MD, Baltimore. Feedback, Motor Sequence Learning, and Brain Connectivity. Motor Learning, Y, All, 18-40, University of South ... ... Xentria, Inc. | Not yet recruiting ➔ Enrolling by invitation. Enrollment open • Immunology • Sarcoidosis. Print; Email; More sharing. Reddit · StumbleUpon. In addition, Victoria is the General Counsel & Corporate Secretary of Xentria, Inc. a biotech company focused on novel biologics and biosimilars, which was ... Sponsor: Xentria, Inc. Overall Status: Active - Recruiting. Phase. 1/2. Condition. Sarcoidosis. Lung Disease. Treatment. XTMAB-16 or Placebo ... Xentria, Inc., a clinical-stage biotherapeutics company focused on developing therapeutics to address unmet clinical needs, today announced ... company logo. XENTRIA INC. 2 of 2 Job Opportunities. All Departments. All Locations. Job, Post Date , Department.